Long-term topical corticosteroid use and altered facial melasma patterns: a retrospective cohort study
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20254116Keywords:
Melasma, Topical corticosteroids, Pigmentary alterations, Post-inflammatory hyperpigmentation, Dermatologic treatmentAbstract
Background: Melasma is a common acquired hyperpigmentation disorder primarily affecting the face. Topical corticosteroids are frequently used, often unsupervised, in melasma management but may induce alteration in pigmentation patterns and adverse sequelae. This study aimed to evaluate the impact of long-term topical corticosteroid use on facial melasma pattern alterations and associated pigmentary sequelae in affected patients.
Methods: A retrospective cohort study was conducted involving 60 patients diagnosed with facial melasma who had a history of prolonged topical corticosteroid use. Baseline demographic and clinical data, corticosteroid usage patterns, changes in melasma distribution, pigmentary sequelae, and clinical outcomes following corticosteroid discontinuation were collected and analyzed descriptively.
Results: The majority were female (n=52, 86.7%) with a mean age of 39.7±9.2 years. Following prolonged steroid exposure, a pigmentary pattern shift was observed in all participants: 40 (66.7%) developed a centrofacial pattern and 16 (26.7%) exhibited a mixed pattern. Post-inflammatory hyperpigmentation (PIH) was noted in 100% of cases. Despite subsequent dermatological treatment and cessation of TCS use, 48 patients (80.0%) reported no clinical improvement, and 52 (86.7%) showed no visible recovery at their final follow-up assessment.
Conclusion: Prolonged topical corticosteroid use in melasma patients is strongly associated with significant alteration in melasma distribution and persistent pigmentary sequelae, highlighting the need for regulated corticosteroid use and increased patient education. Early dermatologic supervision is critical to prevent adverse pigmentary outcomes.
Metrics
References
Sarkar R, Ailawadi P. Treatment of melasma: The journey ahead. Indian J Dermatol. 2017;62(6):555-7. DOI: https://doi.org/10.4103/ijd.IJD_487_17
Pasricha JS, Khaitan BK, Dash S. Pigmentary disorders in India. Dermato Clin. 2007;25(3):343-52. DOI: https://doi.org/10.1016/j.det.2007.05.004
Kong SH, Suh HS, Choi YS. Treatment of melasma with pulsed-dye laser and 1,064-nm Q-switched Nd: YAG laser: a split-face study. Ann Dermatol. 2017;30(1):1. DOI: https://doi.org/10.5021/ad.2018.30.1.1
Melnick S, Lohani S, Alweis R. Hyperpigmentation in a middle aged woman: a common yet underdiagnosed condition. J Comm Hosp Internal Med Perspect. 2016;6(3):31544. DOI: https://doi.org/10.3402/jchimp.v6.31544
Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol. 2005;27(2):96-101. DOI: https://doi.org/10.1097/01.dad.0000154419.18653.2e
Kang WH, Yoon KH, Lee ES, Kim J, Lee KB, Yim H, Sohn S, Im S. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol. 2002;146(2):228-37. DOI: https://doi.org/10.1046/j.0007-0963.2001.04556.x
Nicolaidou E, Antoniou C, Katsambas AD. Origin, clinical presentation, and diagnosis of facial hypermelanoses. Dermatol Clin. 2007;25(3):321-6. DOI: https://doi.org/10.1016/j.det.2007.05.002
Ogbechie-Godec OA, Elbuluk N. Melasma: an up-to-date comprehensive review. Dermatol Therapy. 2017;7:305-18. DOI: https://doi.org/10.1007/s13555-017-0194-1
Achar A, Rathi SK. Melasma: a clinico-epidemiological study of 312 cases. Indian J Dermatol. 2011;56(4):380-2. DOI: https://doi.org/10.4103/0019-5154.84722
Shankar K, Godse K, Aurangabadkar S, Lahiri K, Mysore V, Ganjoo A, et al. Evidence-based treatment for melasma: expert opinion and a review. Dermatol Therapy. 2014;4:165-86. DOI: https://doi.org/10.1007/s13555-014-0064-z
Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1-5. DOI: https://doi.org/10.1016/j.jaad.2005.01.010
Sarkar R, Gokhale N, Godse K, Ailawadi P, Arya L, Sarma N, et al. Medical management of melasma: A review with consensus recommendations by Indian pigmentary expert group. Indian J Dermatol. 2017;62(6):558-77. DOI: https://doi.org/10.4103/ijd.IJD_489_17
Pal D, Biswas P, Das S, De A, Sharma N, Ansari A. Topical steroid damaged/dependent face (TSDF): A study from a tertiary care hospital in Eastern India. Indian J Dermatol. 2018;63(5):375-9. DOI: https://doi.org/10.4103/ijd.IJD_218_17
Kabir Chowdhury MU. Topical corticosteroid abuse: Bangladesh perspective. In: A Treatise on Topical Corticosteroids in Dermatology: Use, Misuse and Abuse. Singapore: Springer Singapore. 2017;197-203. DOI: https://doi.org/10.1007/978-981-10-4609-4_19
Sharma SK, Meher S, Das NR, Dash S, Sharma S. A Descriptive Study of Patients Presenting With Topical Steroid Damaged/Dependent Face (TSDF) to a Tertiary Care Center in Northern India. Cureus. 2024;16(12). DOI: https://doi.org/10.7759/cureus.75566
Saini B, Kumar M, Bandyopadhyay A. Topical corticosteroids induced hyper-pigmentation: a case report. Int J Res. 2019;5(4):889. DOI: https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20194689
Al Dhafiri M, Almutairi M, Alutaibi HM, Aldandan HR, Albshr FA, Alkhalifa FS, et al. Attitude toward using the triple combination bleaching formula and related outcomes: a cross-sectional study. Cureus. 2021;13(12). DOI: https://doi.org/10.7759/cureus.20542
Sharma AN, Kincaid CM, Mesinkovska NA. The Burden of Melasma: Race, Ethnicity, and Comorbidities. J Drugs Dermatol. 2024;23(8):691-3. DOI: https://doi.org/10.36849/JDD.8233
Handel AC, Miot LD, Miot HA. Melasma: a clinical and epidemiological review. Anais Brasileiros de Dermatologia. 2014;89:771-82. DOI: https://doi.org/10.1590/abd1806-4841.20143063
Maymone MB, Neamah HH, Wirya SA, Patzelt NM, Zancanaro PQ, Vashi NA. Sun-protective behaviors in patients with cutaneous hyperpigmentation: A cross-sectional study. J Am Acad Dermatol. 2017;76(5):841-6. DOI: https://doi.org/10.1016/j.jaad.2016.12.018
Basit H, Godse KV, Al Aboud AM. Melasma. Treasure Island (FL): StatPearls Publishing. 2023.
Corrêa-Fissmer M, Mendonça MG, Martins AH, Galato D. Prevalence of self-medication for skin diseases: a systematic review. Anais Brasileiros de Dermatologia. 2014;89(4):625-30. DOI: https://doi.org/10.1590/abd1806-4841.20142872
Karekar SR, Marathe PA, Nagarajan VB, Khopkar US, Chikhalkar SB, Desai PK, et al. Use of topical steroids in dermatology: a questionnaire based study. Indian Dermatol Online J. 2020;11(5):725-30. DOI: https://doi.org/10.4103/idoj.IDOJ_566_19
Gabros S, Nessel TA, Zito PM. Sunscreens and photoprotection. In: StatPearls. StatPearls Publishing. 2023.
Rutnin S, Suchonwanit P, Kositkuljorn C, Pomsoong C, Korpaisarn S, Arunakul J, et al. Characterizing dermatological conditions in the transgender population: a cross-sectional study. Transgender Health. 2023;8(1):89-99. DOI: https://doi.org/10.1089/trgh.2021.0105
Lawrence E, Syed HA, Al Aboud KM. Postinflammatory hyperpigmentation. InStatPearls. StatPearls Publishing. 2024.
Bandyopadhyay D. Topical treatment of melasma. Indian J Dermatol. 2009;54(4):303-9. DOI: https://doi.org/10.4103/0019-5154.57602
Jo JY, Chae SJ, Ryu HJ. Update on melasma treatments. Ann Dermatol. 2024;36(3):125. DOI: https://doi.org/10.5021/ad.23.133
Downloads
Published
How to Cite
Issue
Section
